ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver ...
MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback